Brendan Bulik-Sullivan

Brendan Bulik-Sullivan is a General Partner at GV (Google Ventures) backing biotech and therapeutics companies from the San Francisco office. He arrived at venture capital by a back door familiar to almost no one: a Ph.D. in statistical genetics, an authorship on the LD Score Regression method that reshaped how human geneticists read GWAS data, and a stint designing the deep-learning neoantigen models at Gritstone Oncology. He now sits on the boards of Comanche Biopharma, Santa Ana Bio, Ventus Therapeutics, and Areteia Therapeutics.